GlaxoSmithKline PLC is hoping to use evidence from a “real-world” trial to convince payers that Breo Ellipta (fluticasone/vilanterol) is worth paying for. The aim is to collect data showing Breo, GSK’s new, once-daily inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA) for chronic obstructive pulmonary disease (COPD) improves patient adherence compared with existing twice-daily ICS/LABA treatments and that as a result it improves health outcomes.
To support its case, in 2012, the company initiated an innovative clinical trial called the Salford Lung Study, testing with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?